Paragraf Ltd. is a graphene technology development company based in Somersham, United Kingdom, established in 2015. The company specializes in the production of two-dimensional materials, particularly graphene, and focuses on developing graphene-based electronic devices, green energy generation devices such as solar photovoltaic cells, and various sensors. By leveraging innovative methods, Paragraf aims to unlock the full potential of graphene and advance its applications across multiple technology sectors. The company's commitment to driving the adoption of this versatile material positions it as a key player in the field of advanced materials and their transformative capabilities.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Novadip Biosciences SA is a biopharmaceutical company that develops process and distribution platform for tissue regeneration. It focuses on autologous cell therapies for critical size tissue reconstruction; allogeneic therapeutics for smaller and prevalent tissue defects; and miRNA/exosome-based therapeutics for systemic tissue and other diseases. The company was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.
BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.
Phase Four LLC manufactures satellite propulsion systems. It also provides CubeSats ambipolar thruster, an electrodeless permanent magnet helicon thruster; and Maxwell, a turn key plasma propulsion solution for small satellites. The company’s products are used in commercial, civil, and scientific space missions. The company was incorporated in 2015 and is based in Pasadena, California.
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.
Zeotap GmbH is a customer intelligence platform that assists brands in understanding their customers and predicting their behaviors, which enables more effective investments in customer relationships and products. Established in 2014 and headquartered in Berlin, Germany, Zeotap combines identity and profile data from exclusive enterprise partners with a comprehensive technology platform for unifying first-party customer data, identity resolution, third-party data enrichment, and analytics. The company emphasizes data privacy and security, adhering to strict governance and compliance measures, and holds certifications such as ISO 27001 and CSA STAR. Zeotap serves over 70 of the top 100 global brands, including Unilever, BBVA, and Mercedes-Benz, and has expanded its operations to locations such as New York, Bengaluru, Madrid, and Milan. With a workforce of 145 employees, Zeotap has raised more than $45 million from international investors.
ABL Space Systems is a company focused on designing and manufacturing low-cost rockets for the small satellite market. Founded in 2017 by former SpaceX engineers, the company is headquartered in El Segundo, California, where it operates facilities covering 30,000 square feet dedicated to research, development, and production. ABL's primary launch vehicle, the RS1, is designed to support various configurations for deploying small satellites, including multi-manifest and dedicated launches. The company's innovative approach features a simplified tank architecture and advanced propellant management systems, which aim to enhance the efficiency and routine nature of orbital launches. As a privately-owned entity, ABL is backed by a group of prominent private equity investors.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
DUST Identity, Inc. specializes in developing an authentication system that employs nano-diamonds to create an unclonable identity layer on various objects for supply chains. This technology, known as DUST, links physical items to their digital records, allowing for secure verification and authentication. The company also offers an optical scanner and a cloud-based infrastructure that facilitates access to object identity and provenance information. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, DUST Identity aims to ensure that trusted data and verifiable products can be traced throughout their lifecycle, thus enhancing safety and reliability in product sourcing, testing, and certification.
PlanetiQ LLC, established in 2012 and headquartered in Bethesda, Maryland, is dedicated to launching satellites that enhance weather forecasting, climate monitoring, and space weather prediction. As the demand for global atmospheric data increases due to rising natural disaster costs and the impacts of climate change, traditional government-funded satellite programs struggle to meet these needs. Aging spacecraft and budget constraints contribute to significant data gaps that hinder accurate monitoring and forecasting of daily weather events, hurricanes, floods, droughts, and long-term climate trends. By addressing these challenges, PlanetiQ aims to provide timely and precise atmospheric data to improve weather and climate models, ultimately benefiting public safety and environmental management.
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.
BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.
DUST Identity, Inc. specializes in developing an authentication system that employs nano-diamonds to create an unclonable identity layer on various objects for supply chains. This technology, known as DUST, links physical items to their digital records, allowing for secure verification and authentication. The company also offers an optical scanner and a cloud-based infrastructure that facilitates access to object identity and provenance information. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, DUST Identity aims to ensure that trusted data and verifiable products can be traced throughout their lifecycle, thus enhancing safety and reliability in product sourcing, testing, and certification.
Svelte Medical Systems, Inc. is a privately held company that specializes in the design and development of innovative balloon-expandable stents for patients undergoing percutaneous coronary interventions to treat atherosclerosis. Founded in 2007, the company is based in New Providence, New Jersey, and aims to address critical clinical issues in the coronary stent market, which is valued at approximately $5 billion. Svelte offers two primary products: the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire designed to facilitate transradial interventions, and the DIRECT Rapid Exchange System, which enhances direct stenting and high-pressure post-dilatations. Both systems utilize proprietary technologies to improve stent deliverability, reduce the need for additional guide wires and balloons, and ultimately enhance patient outcomes while minimizing procedure costs and risks.
Isorg SA, founded in 2010 and based in Grenoble, France, specializes in the development and manufacturing of organic and printed electronic devices, particularly in the fields of photonics and image sensors. The company is noted for its innovative high-performance opto-electronic sensors, which can be integrated into various products, transforming surfaces made of plastic or glass into smart interfaces. Isorg offers a comprehensive range of services, from proof-of-concept to mass production, catering to diverse applications across consumer electronics, home appliances, smart buildings, industrial sectors, healthcare, and safety. Additionally, the company provides support for product development and integration. Its technology includes large-area image sensors and photodetectors, contributing to sectors such as medical imaging, non-destructive testing, and data security.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.
Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands with offices in Nijmegen, The Netherlands and Encinitas, California.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Zeotap GmbH is a customer intelligence platform that assists brands in understanding their customers and predicting their behaviors, which enables more effective investments in customer relationships and products. Established in 2014 and headquartered in Berlin, Germany, Zeotap combines identity and profile data from exclusive enterprise partners with a comprehensive technology platform for unifying first-party customer data, identity resolution, third-party data enrichment, and analytics. The company emphasizes data privacy and security, adhering to strict governance and compliance measures, and holds certifications such as ISO 27001 and CSA STAR. Zeotap serves over 70 of the top 100 global brands, including Unilever, BBVA, and Mercedes-Benz, and has expanded its operations to locations such as New York, Bengaluru, Madrid, and Milan. With a workforce of 145 employees, Zeotap has raised more than $45 million from international investors.
Caringo, Inc. is a software provider specializing in object storage solutions for unstructured data. The company's primary product, CAStor, enables users to create private cloud storage that enhances the efficiency and cost-effectiveness of content storage by allowing the establishment of scalable storage clusters without reliance on proprietary hardware. Additionally, Caringo offers various products such as the Content Router for automated data distribution, the FileFly platform for managing infrequently accessed data on Windows servers, and the Elastic Content Protection solution for flexible data safeguarding. Their CloudScaler product allows organizations to provide cloud storage as a service, while the Indexer delivers insights into stored data. With a client base that includes both small and mid-sized businesses as well as Fortune 500 companies, Caringo's approach emphasizes simplicity and customer-centric solutions, enabling effective data management and access. Founded in 2005 and headquartered in Austin, Texas, Caringo continues to innovate in the field of data storage and management.
BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.
VUV Analytics, Inc. specializes in the manufacture and marketing of vacuum ultraviolet (VUV) detectors, which enhance chemical analysis accuracy through advanced spectroscopy techniques. Established in 2009 as a spin-off from a semiconductor equipment company, VUV Analytics leverages the expertise of its founders, who possess extensive knowledge in hardware, software, analysis, and intellectual property related to VUV technologies. The company offers products such as the VGA-100, a VUV absorption spectroscopy instrument, and gas chromatography detectors, which are utilized for both identification and quantification of various compounds. Its technology finds applications across multiple industries, including petroleum and natural gas, environmental science, petrochemicals, agrochemicals, and food and beverage safety. VUV Analytics is headquartered in Cedar Park, Texas, and has developed a substantial intellectual property portfolio, including numerous issued and pending patents.
Kateeva, formerly known as TJet Technologies, specializes in developing advanced inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions facilitate the mass production of flexible and large-size OLEDs, enabling high-speed printing of billions of pixels. This technology significantly enhances production efficiency by lowering costs, increasing yields, and extending the lifespan of OLED displays. Kateeva's equipment represents a groundbreaking approach to OLED manufacturing, making it economically viable for the production of high-quality flat panel displays. This advancement is poised to revolutionize the display industry, paving the way for consumer electronics such as ultra-thin OLED TVs and lightweight wearable devices.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Private Equity Round in 2016
Svelte Medical Systems, Inc. is a privately held company that specializes in the design and development of innovative balloon-expandable stents for patients undergoing percutaneous coronary interventions to treat atherosclerosis. Founded in 2007, the company is based in New Providence, New Jersey, and aims to address critical clinical issues in the coronary stent market, which is valued at approximately $5 billion. Svelte offers two primary products: the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire designed to facilitate transradial interventions, and the DIRECT Rapid Exchange System, which enhances direct stenting and high-pressure post-dilatations. Both systems utilize proprietary technologies to improve stent deliverability, reduce the need for additional guide wires and balloons, and ultimately enhance patient outcomes while minimizing procedure costs and risks.
Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics aimed at treating inflammatory and fibrotic diseases. Headquartered in Cambridge, United Kingdom, with an additional office in San Diego, California, the company has been working on a lead program involving a non-bile acid FXR agonist. This therapeutic candidate targets nonalcoholic steatohepatitis (NASH), a progressive fatty-liver disease for which there are currently no approved treatment options. As of August 2016, Akarna operates as a subsidiary of Allergan plc. The lead candidate is in the preclinical phase, undergoing toxicology and safety pharmacology studies, with plans for first-in-human trials in the near future.
Ovizio Imaging Systems NV/SA specializes in the development of digital holographic interferometric microscopy products, creating advanced 4D microscopic imaging devices and software. Founded in 2009 and headquartered in Brussels, Belgium, the company offers a range of devices, including the oLine 4D, which requires no specific sample preparation and compensates for sample imperfections; the iLine 4D, designed for various applications such as flow monitoring and cell culture observation; and various specialized instruments like ILine F for real-time monitoring of suspension cell cultures and iLine M for assessing cell confluence in multi-layer vessels. Ovizio also provides OsOne software for the visualization, analysis, and archiving of captured images, alongside QMod, which integrates holographic and fluorescence microscopy. Its products are widely utilized by scientists in pharmaceutical and biotechnology research and development, facilitating advancements in automated cell culture monitoring and analysis.
Fuzzy Logix, LLC is an analytics software and professional services company headquartered in Charlotte, North Carolina. Founded in 1995, it specializes in in-database analytics solutions that enable organizations to perform computations directly within their databases, eliminating the need for data extraction and intermediary analytics servers. Its flagship product, DB Lytix, serves quantitative analysts and application developers by facilitating in-database scoring and model development, thereby accelerating the analytical process. The company also offers a range of tools, including a financial analytics solution and the Tanay ZXnW Series, an analytic appliance equipped with a comprehensive library of algorithms. Additionally, Fuzzy Logix provides various services such as analytics advisory, cloud analytics, and custom model development. Its clientele spans multiple sectors, including finance, insurance, marketing, retail, and healthcare, and its products are available both directly and through resellers in the U.S. and internationally.
EXTEN provides high-performance storage software to hyperscale data centers. EXTEN’s agile, reliable, and scalable solution is well suited for the most demanding high-performance, low-latency workloads where needs are highly variable and unpredictable including e-commerce, real-time analytics, and video processing, financial and trading applications, transaction processing, and buffering workloads with large-scale file systems. Founded in 2012, EXTEN Technologies is a pioneer in ultra-high-performance NVMe over Fabrics storage software applications. EXTEN is venture capital funded and is based in Austin, Texas.
Novadip Biosciences SA is a biopharmaceutical company that develops process and distribution platform for tissue regeneration. It focuses on autologous cell therapies for critical size tissue reconstruction; allogeneic therapeutics for smaller and prevalent tissue defects; and miRNA/exosome-based therapeutics for systemic tissue and other diseases. The company was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.
Vorago Technologies Inc. is a privately held fabless semiconductor company based in Austin, Texas, that specializes in the design, manufacturing, and testing of radiation-hardened and extreme temperature-hardened integrated circuit (IC) components. Founded in 2004 and formerly known as Silicon Space Technology, Vorago develops high-density SRAMs and microcontrollers tailored for automotive, industrial, military, aerospace, and networking applications. The company utilizes its patented HARDSIL technology to enhance the radiation and temperature endurance of ICs without requiring redesigns, making it scalable across various CMOS process generations. In addition to memory solutions like 16Mb asynchronous and 8Mb dual-port synchronous SRAMs, Vorago offers custom application-specific integrated circuit (ASIC) design services leveraging its hardened Metal Programmable System On Chip (MPSoC) platform. This innovative approach provides a reliable alternative to traditional high-reliability methods, ensuring that integrated circuits can perform effectively in extreme environments.
Ralexar Therapeutics, Inc. is a biopharmaceutical company focused on developing and manufacturing topical and systemic therapies that utilize Liver X Receptor (LXR) modulators. The company targets a range of cutaneous inflammatory disorders, with a particular emphasis on atopic dermatitis. Founded in 2013 and headquartered in Wayne, Pennsylvania, Ralexar is known for its clinical development of ALX-101, a topical therapy designed to improve treatment outcomes for patients with dermatological conditions. Originally established as Alexar Therapeutics, the company rebranded in March 2016 and operates as a subsidiary of NeXeption, LLC.
PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.
Vaultive specializes in cloud data encryption services, focusing on enhancing data security for businesses transitioning to cloud environments. The company's innovative technology allows organizations to encrypt their data while still enabling it to be searched, indexed, and processed within cloud applications without the need for decryption. This approach empowers customers to maintain control and ownership of their data, as they hold the encryption keys. By doing so, Vaultive ensures that businesses can utilize cloud applications efficiently while adhering to governance and compliance requirements, effectively mitigating the risks associated with cloud data storage.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Kateeva, formerly known as TJet Technologies, specializes in developing advanced inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions facilitate the mass production of flexible and large-size OLEDs, enabling high-speed printing of billions of pixels. This technology significantly enhances production efficiency by lowering costs, increasing yields, and extending the lifespan of OLED displays. Kateeva's equipment represents a groundbreaking approach to OLED manufacturing, making it economically viable for the production of high-quality flat panel displays. This advancement is poised to revolutionize the display industry, paving the way for consumer electronics such as ultra-thin OLED TVs and lightweight wearable devices.
Svelte Medical Systems, Inc. is a privately held company that specializes in the design and development of innovative balloon-expandable stents for patients undergoing percutaneous coronary interventions to treat atherosclerosis. Founded in 2007, the company is based in New Providence, New Jersey, and aims to address critical clinical issues in the coronary stent market, which is valued at approximately $5 billion. Svelte offers two primary products: the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire designed to facilitate transradial interventions, and the DIRECT Rapid Exchange System, which enhances direct stenting and high-pressure post-dilatations. Both systems utilize proprietary technologies to improve stent deliverability, reduce the need for additional guide wires and balloons, and ultimately enhance patient outcomes while minimizing procedure costs and risks.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.
Ario Pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.
BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.
Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds for the treatment of cardiovascular diseases associated with dyslipidemia. The company specializes in creating novel drugs, including a cholesteryl ester transfer protein inhibitor, aimed at lowering low-density lipoprotein cholesterol levels. By addressing these lipid imbalances, Dezima Pharma provides clinicians with pharmacological therapies that can effectively treat patients suffering from dyslipidemic-related cardiovascular conditions.
Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focusing on the development of biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product, RSLV-125, through preclinical research and into phase IIa clinical trials. Additionally, it has developed RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby preventing interferon activation and mitigating kidney damage. Another product, RSLV-133, is a bi-specific Fc-nuclease fusion protein that combines two distinct nuclease activities into a single drug molecule. Founded in 2010, Resolve Therapeutics is built on the groundbreaking research of Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a mission to improve the lives of lupus patients.
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
Juventas Therapeutics, Inc., a clinical stage biotechnology company, develops non-viral gene therapies that activate natural processes to repair the body. The company focuses on treatment of non-healing wounds in patients with advanced peripheral artery disease. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1 or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a range of disease states. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
Vaultive specializes in cloud data encryption services, focusing on enhancing data security for businesses transitioning to cloud environments. The company's innovative technology allows organizations to encrypt their data while still enabling it to be searched, indexed, and processed within cloud applications without the need for decryption. This approach empowers customers to maintain control and ownership of their data, as they hold the encryption keys. By doing so, Vaultive ensures that businesses can utilize cloud applications efficiently while adhering to governance and compliance requirements, effectively mitigating the risks associated with cloud data storage.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.
Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focusing on the development of biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product, RSLV-125, through preclinical research and into phase IIa clinical trials. Additionally, it has developed RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby preventing interferon activation and mitigating kidney damage. Another product, RSLV-133, is a bi-specific Fc-nuclease fusion protein that combines two distinct nuclease activities into a single drug molecule. Founded in 2010, Resolve Therapeutics is built on the groundbreaking research of Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a mission to improve the lives of lupus patients.
Lightwire’s mission is to deliver efficient integration of optical and electrical solutions which will power the next generation of high speed interconnects using CMOS photonics technology.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Seahorse Bioscience specializes in the development of analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company's flagship products include the Seahorse Extracellular Flux (XF) analyzers, which enable scientists to non-invasively measure the metabolic activity of cells. These instruments provide valuable insights into various cellular processes, including basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, facilitating research into mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including academic institutions, pharmaceutical and biotech companies, as well as OEM manufacturers of assay kits and laboratory instruments.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Seahorse Bioscience specializes in the development of analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company's flagship products include the Seahorse Extracellular Flux (XF) analyzers, which enable scientists to non-invasively measure the metabolic activity of cells. These instruments provide valuable insights into various cellular processes, including basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, facilitating research into mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including academic institutions, pharmaceutical and biotech companies, as well as OEM manufacturers of assay kits and laboratory instruments.
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
TherOx, Inc. is a medical device company based in Irvine, California, focused on enhancing the treatment standards for heart attack patients. Founded in 1994, the company specializes in developing and manufacturing dissolved oxygen delivery systems, specifically through its proprietary SuperSaturated Oxygen Therapy (SSO2). The TherOx DownStream system is a mobile device that works in conjunction with a cartridge and console to create a superoxygenated solution mixed with the patient’s blood, which is then delivered to the coronary arteries. This innovative approach aims to restore blood flow and promote healing in damaged heart tissue. In addition to its primary application in heart attack treatment, TherOx has identified potential uses for its technology in other medical fields, including stroke, oncology, and wound care. The company holds 20 issued patents, with additional applications pending. As of June 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Ikonisys, Inc. specializes in designing and manufacturing medical diagnostic products aimed at cancer diagnosis and genetic disorder detection in the United States and Europe. The company offers a range of innovative products, including the Ikoniscope Robotic Microscope, which automates slide handling, scanning, and real-time image analysis to minimize human error in testing. Key applications include oncoFISH bladder for analyzing urine samples, oncoFISH her2 for assessing HER2 status in breast tissue, and oncoFISH PTEN for detecting PTEN gene deletions in prostate biopsies. Additionally, Ikonisys provides FISH scanning applications for both cell suspensions and various tissue sections, along with the IkoniWAN Gateway, a remote access solution for digital microscopy systems. Founded in 1999 and headquartered in New Haven, Connecticut, Ikonisys is committed to advancing diagnostic medicine through early and non-invasive disease detection, thereby enhancing patient management.
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.
Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Ikonisys, Inc. specializes in designing and manufacturing medical diagnostic products aimed at cancer diagnosis and genetic disorder detection in the United States and Europe. The company offers a range of innovative products, including the Ikoniscope Robotic Microscope, which automates slide handling, scanning, and real-time image analysis to minimize human error in testing. Key applications include oncoFISH bladder for analyzing urine samples, oncoFISH her2 for assessing HER2 status in breast tissue, and oncoFISH PTEN for detecting PTEN gene deletions in prostate biopsies. Additionally, Ikonisys provides FISH scanning applications for both cell suspensions and various tissue sections, along with the IkoniWAN Gateway, a remote access solution for digital microscopy systems. Founded in 1999 and headquartered in New Haven, Connecticut, Ikonisys is committed to advancing diagnostic medicine through early and non-invasive disease detection, thereby enhancing patient management.
Light Sciences Oncology, Inc. develops and manufactures talaporfin sodium for the treatment of tumors and other indications in patients. The company also offers drug activator, an LED based single use disposable device that provides a fixed light dose. Its drug is used for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia and enlargement of the prostate. The company was founded in 1994 and is based in Bellevue, Washington.
TherOx, Inc. is a medical device company based in Irvine, California, focused on enhancing the treatment standards for heart attack patients. Founded in 1994, the company specializes in developing and manufacturing dissolved oxygen delivery systems, specifically through its proprietary SuperSaturated Oxygen Therapy (SSO2). The TherOx DownStream system is a mobile device that works in conjunction with a cartridge and console to create a superoxygenated solution mixed with the patient’s blood, which is then delivered to the coronary arteries. This innovative approach aims to restore blood flow and promote healing in damaged heart tissue. In addition to its primary application in heart attack treatment, TherOx has identified potential uses for its technology in other medical fields, including stroke, oncology, and wound care. The company holds 20 issued patents, with additional applications pending. As of June 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.